Peihua Luo

2.4k total citations
94 papers, 1.8k citations indexed

About

Peihua Luo is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Peihua Luo has authored 94 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Molecular Biology, 25 papers in Oncology and 16 papers in Hematology. Recurrent topics in Peihua Luo's work include PI3K/AKT/mTOR signaling in cancer (13 papers), Autophagy in Disease and Therapy (12 papers) and Chronic Myeloid Leukemia Treatments (11 papers). Peihua Luo is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (13 papers), Autophagy in Disease and Therapy (12 papers) and Chronic Myeloid Leukemia Treatments (11 papers). Peihua Luo collaborates with scholars based in China, United States and Canada. Peihua Luo's co-authors include Qiaojun He, Bo Yang, Hao Yan, Zhifei Xu, Xiaochun Yang, Ying Jin, Hong Zhu, Guanqun Li, Jian Chen and Xueqin Chen and has published in prestigious journals such as Nature Communications, PLoS ONE and Cancer Research.

In The Last Decade

Peihua Luo

85 papers receiving 1.8k citations

Peers

Peihua Luo

ONCOL

PRM

IMMUN

Long Wang China

Vincent C. Daniel United States

Bart Jessen United States

Yahui Ding China

Guoqing Cao China

Ellis W.T. Wong Italy

Dong Chen China

Chae Hwa Kwon South Korea

Ke Lin United Kingdom

Xiaoqing Shi China

Long Wang China

Peihua Luo

1.3k ×1.4

745 ×1.6

ONCOL

197 ×0.7

PRM

397 ×1.8

IMMUN

293 ×1.5

Citations per year, relative to Peihua Luo Peihua Luo (= 1×) peers Long Wang

Countries citing papers authored by Peihua Luo

Since Specialization

Citations

This map shows the geographic impact of Peihua Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peihua Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peihua Luo more than expected).

Fields of papers citing papers by Peihua Luo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peihua Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peihua Luo. The network helps show where Peihua Luo may publish in the future.

Co-authorship network of co-authors of Peihua Luo

This figure shows the co-authorship network connecting the top 25 collaborators of Peihua Luo. A scholar is included among the top collaborators of Peihua Luo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peihua Luo. Peihua Luo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cheng, Mengting, Wentong Wu, Xiu‐Qing Li, et al.. (2025). Sotorasib-impaired degradation of NEU1 contributes to cardiac injury by inhibiting AKT signaling. Cell Death Discovery. 11(1). 169–169.

Yan, Hao, Mu Yuan, Zhifei Xu, et al.. (2025). Disturbing Cholesterol/Sphingolipid Metabolism by Squalene Epoxidase Arises Crizotinib Hepatotoxicity. Advanced Science. 12(14). e2414923–e2414923. 2 indexed citations

Cheng, Mengting, Yunfang Zhou, Ting Liu, et al.. (2024). Dabrafenib alleviates hepatotoxicity caused by lenvatinib via inhibiting the death receptor signaling pathway. Toxicology Letters. 397. 163–173.

Luo, Peihua, et al.. (2024). DKVMN-KAPS: Dynamic Key-Value Memory Networks Knowledge Tracing With Students’ Knowledge-Absorption Ability and Problem-Solving Ability. IEEE Access. 12. 55146–55156. 2 indexed citations

Cheng, Mengting, Fei Wang, Zhifei Xu, et al.. (2024). Underlying mechanisms and management strategies for regorafenib-induced toxicity in hepatocellular carcinoma. Expert Opinion on Drug Metabolism & Toxicology. 20(9). 907–922.

Xu, Zhifei, Bo Yang, Qiaojun He, et al.. (2023). An update on Alectinib: a first line treatment for ALK-positive advanced lung cancer. Expert Opinion on Pharmacotherapy. 24(12). 1361–1373. 1 indexed citations

Yang, Xiaochun, Zhifei Xu, Bo Yang, et al.. (2023). The participation of non-canonical autophagic proteins in the autophagy process and their potential as therapeutic targets. Expert Opinion on Therapeutic Targets. 27(1). 71–86. 1 indexed citations

Yan, Hao, Jinjin Li, Xueqin Chen, et al.. (2023). Regorafenib inhibits EphA2 phosphorylation and leads to liver damage via the ERK/MDM2/p53 axis. Nature Communications. 14(1). 2756–2756. 31 indexed citations

Yan, Hao, Ying Zhang, Jiajia Chen, et al.. (2023). Chloroquine Intervenes Nephrotoxicity of Nilotinib through Deubiquitinase USP13‐Mediated Stabilization of Bcl‐XL. Advanced Science. 10(26). e2302002–e2302002. 9 indexed citations

10.

Yan, Hao, Xiaochun Yang, Bo Yang, et al.. (2022). Dasatinib causes keratinocyte apoptosis via inhibiting high mobility group Box 1-mediated mitophagy. Toxicology Letters. 373. 22–32. 5 indexed citations

11.

Xu, Zhifei, Ying Jin, Yan Zeng, et al.. (2021). Autophagic degradation of CCN2 (cellular communication network factor 2) causes cardiotoxicity of sunitinib. Autophagy. 18(5). 1152–1173. 44 indexed citations

12.

Xu, Zhifei, et al.. (2021). Regulation of p53 stability as a therapeutic strategy for cancer. Biochemical Pharmacology. 185. 114407–114407. 34 indexed citations

13.

Wang, Zeng, Liyu Jiang, Hao Yan, Zhifei Xu, & Peihua Luo. (2021). Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies. Expert Review of Clinical Pharmacology. 14(4). 445–456. 14 indexed citations

14.

Yan, Hao, Zhifei Xu, Bo Yang, et al.. (2021). Cutaneous toxicity of FDA-approved small-molecule kinase inhibitors. Expert Opinion on Drug Metabolism & Toxicology. 17(11). 1311–1325. 6 indexed citations

15.

Jiang, Liyu, et al.. (2020). COVID-19 epidemic: a special focus on diagnosis, complications, and management. Expert Review of Clinical Pharmacology. 13(10). 1085–1093. 2 indexed citations

16.

Chen, Jian, Hao Yan, Qiaojun He, et al.. (2020). <p>Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy</p>. Drug Design Development and Therapy. Volume 14. 3625–3649. 139 indexed citations

17.

Jiang, Liyu, Ping Li, Hao Yan, et al.. (2020). Cardiovascular toxicity induced by anti-VEGF/VEGFR agents: a special focus on definitions, diagnoses, mechanisms and management. Expert Opinion on Drug Metabolism & Toxicology. 16(9). 823–835. 16 indexed citations

18.

Zhu, Hong, Dandan Wang, Tao Yuan, et al.. (2018). Multikinase Inhibitor CT-707 Targets Liver Cancer by Interrupting the Hypoxia-Activated IGF-1R–YAP Axis. Cancer Research. 78(14). 3995–4006. 34 indexed citations

19.

Wang, Dandan, Ying Chen, Zibo Chen, et al.. (2016). CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation. Molecular Cancer Therapeutics. 15(12). 2916–2925. 38 indexed citations

20.

Ying, Meidan, Xinglu Zhou, Like Zhong, et al.. (2012). Bortezomib Sensitizes Human Acute Myeloid Leukemia Cells to All- Trans -Retinoic Acid–Induced Differentiation by Modifying the RARα/STAT1 Axis. Molecular Cancer Therapeutics. 12(2). 195–206. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact